1. 00070 A MULTICENTRE PHASE II TRIAL OF GEFITINIB 500 MG/ DAY IN PATIENTS WITH RECURRENT EGFR-POSITIVE GYNAECOLOGICAL TUMOURS. (1st September 2005) Authors: Vergote, I.; Amant, F.; Forget, F.; Canon, J. L.; Awada, A.; Dirix, L.; Van Belle, S. Journal: International journal of gynecological cancer Issue: Volume 15(2005)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC). (September 2015) Authors: Cortes, J.; Crown, J.; Awada, A.; Schmid, P.; Gianni, L.; Garcia-Estevez, L.; Martinez-Janez, N.; Chan, S.; Steinberg, J.L.; Blaney, M.; Tudor, I.C.; Uppal, H.; Peterson, A.; Miller, K.; Yardley, D.A.; Hudis, C.A.; Traina, T.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985. (September 2015) Authors: Van Herpen, C.M.; Banerji, U.; Mommers, E.C.; Koper, N.P.; Goedings, P.; Lopez, J.; Awada, A.; Fiebrich, H.B.; Aftimos, P.G. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours. (September 2015) Authors: Spicer, J.; Awada, A.; Brunsvig, P.; Saunders, A.; Olsen, W.M.; Nicolaisen, B.; Rekdal, O.; Laruelle, M.; Marjuadi, F.; Vakili, J.; Aftimos, P.; Barthelemy, P.; Deva, S.; Baurain, J.F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors. (December 2016) Authors: Massard, C.; Soria, J.C.; Stathis, A.; Delord, J.P.; Awada, A.; Peters, S.; Lewin, J.; Bekradda, M.; Rezai, K.; Zeng, Z.; Azher, H.; Perez, S.; Siu, L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate. Issue 6 (3rd June 2019) Authors: Kotecki, N.; Gombos, A.; Awada, A. Journal: Expert review of anticancer therapy Issue: Volume 19:Issue 6(2019) Page Start: 447 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Current management of ovarian carcinosarcoma. Issue 2 (1st February 2007) Authors: Mano, M. S.; Rosa, D. D.; Azambuja, E.; Ismael, G.; Braga, S.; D'HONDT, V.; Piccart, M.; Awada, A. Journal: International journal of gynecological cancer Issue: Volume 17:Issue 2(2007) Page Start: 316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. How do cancer centres communicate clinical trials opportunities to patients on their websites?. (February 2017) Authors: Miqueu, P.; Awada, A.; De Valeriola, D.; Piccart, M. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. (February 2016) Authors: Lalami, Y.; Awada, A. Journal: Cancer treatment reviews Issue: Volume 43(2016) Page Start: 113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. INTRAPERITONEAL (IP) CISPLATIN (P) VERSUS NO FURTHER TREATMENT: 8 YEAR-RESULTS OF AN EORTCGCG RANDOMIZED PHASE III STUDY IN OVARIAN CANCER (O.C.) PATIENTS (PTS) WITH A PATHOLOGICALLY COMPLETE REMISSION (PCR) AFTER P-BASED INDUCTION CHEMOTHERAPY (CT) AND CYTOREDUCTIVE SURGERY. Issue 1 (1st March 2003) Authors: Piccart, M. J.; Floquet, A.; Scarfone, G.; Willemse, P. H.B.; Kobierska, A.; Chevallier, B.; Awada, A.; Vergote, I.; Giurgea, L.; Coens, C.; Vermorken, J. Journal: International journal of gynecological cancer Issue: Volume 13:Issue 1(2003) Supplement Page Start: 8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗